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The 94-kD large tumor (T) antigen specified by simian virus 40 (SV40) is sufficient to induce 
cell transformation. T  antigen contains four H-2Db-restricted cytotoxic T  lymphocyte (CTL) 
recognition epitopes that are targets for CTL clones Y-l, Y-2, Y-3, and Y-5. These epitopes have 
been mapped to T antigen amino acids 207-215  (site I), 223-231 (sites II and III), and 489-497 
(site V), respectively. Antigenic site loss variant cells that had lost one or more CTL recognition 
epitopes were previously selected by coculturing SV40-transformed H-2D  b cells with the site- 
specific Db-restricted CTL dones. The genetic bases for T antigen CTL recognition epitope loss 
from the variant cells were identified by DNA amplification and direct sequencing of epitope- 
coding regions from variant cell DNAs. Cells  selected for resistance  to CTL done Y-1 (K-l; 
K-1,4,5;  K-3,1) carry deleted SV40 genomes lacking site I, II, and III coding sequences. Point 
mutations present within the site II/III coding region of Y-2-/Y-3-resistant  cell lines specify 
the substitution of asparagine for lysine as T  antigen amino acid 228  (I(-2)  or phenylalanine 
for tyrosine at position 230 (K-3). Point mutations identified within independently selected Y-5 
resistant populations (K-5 and K-1,4,5)  direct the substitution of isoleucine for asparagine  at 
position 496 (K-5) or the substitution of phenylalanine for isoleucine at position 491 (K-1,4,5) 
of T antigen. Each substitution causes loss of the relevant CTL recognition epitope, apparently 
by compromising CTL T cell receptor recognition. These experiments identify specific amino 
acid changes within a transforming protein that facilitate transformed cell escape from site-specific 
CTL clones while allowing maintenance of cellular  transformation. This experimental model 
system provides unique opportunities for studying mechanisms of transformed cell escape from 
active immunosurveillance  in vivo, and for analysis of differential host immune responses to wild- 
type and mutant cell-transforming proteins. 
T 
umors induced by DNA viruses acquire spedfic antigens 
that provide targets for T lymphocyte-mediated  immune 
responses modulating tumor cell growth in vivo and abroga- 
ting cellular transformation in vitro (1-4).  Specific CTL rec- 
ognition of tumor cells requires the presentation by MHC 
class I molecules of processed tumor antigen to the T lym- 
phocyte antigen receptor. Tumor cell variants that escape CTL 
immunosurveiUance  have been described (5-18).  In most in- 
stances, the emergence of CTL escape variant cells is associated 
with the decrease or absence of MHC class I  antigens re- 
quired for antigen recognition by CTL (11-16). In other cases, 
a complete loss of tumor antigen from the variants has been 
reported (6,  10,  17-19). 
Molecular studies indicate that mutations within individual 
cellular genes can induce the formation of new CTL recog- 
nition epitopes (20). In the P815 mouse mastocytoma tumor 
system, nontumorigenic variants (turn-) 1 of tumorigenic 
P815 cells (turn +) were isolated after chemical mutagenesis 
of the turn + cells (21). The decrease in tumorigenicity ob- 
served  for  turn-  cells  correlated with  the  acquisition of 
genomic point mutations creating new CTL antigenicities 
recognized by  turn--specific  CTL  (21-25).  Antigen-loss 
variant cells were obtained by cocultivating tum- "antigen- 
gain" variant cells with CTL specific for the new turn- 
1 Abbreviations used in this paper:  nt, nucleotide; SV40, simian virus 40; 
T, large tumor; turn-, nontumorigenic; turn+,  tumorigenic. 
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tion within a gene encoding a turn-  CTL recognition epi- 
tope was demonstrated (26). However, the loss of CTL rec- 
ognition sites from antigen-loss variant tumor cells because 
of spontaneous point mutations in CTL recognition epitope 
coding sequences  has not been reported. 
The simian virus 40 (SV40) large tumor (T) antigen, a 
94-kD protein that is sufficient to induce transformation of 
mammalian cells to malignancy (27), serves as a tumor rejec- 
tion antigen (28, 29). In context, portions of T antigen form 
epitopes recognized by T  antigen-specific CTL. The T  an- 
tigen contains four H-2Db-restricted CTL recognition sites 
recognized by site-specific CTL clones Y-l, Y-2, Y-3, and Y-5 
(28,  30),  and one H-2Kb-restricted site recognized by CTL 
clone Y-4 (28).  These CTL recognition epitopes are desig- 
nated sites I, II, III, V, and IV, respectively. CTL recognition 
site I maps to T  antigen amino acids 207-215  (31); sites II 
and III lie within T  antigen amino acids 223-231  (31); and 
site V was first mapped within amino acids 489-503  (30). 
Recent experiments have delimited site V within T antigen 
amino acids 489-497 (31). Site IV lies within T antigen amino 
acids 369-511. 
To define the mechanisms of spontaneous loss of functional 
CTL recognition sites from tumor antigens, we have ana- 
lyzed the T antigen CTL recognition epitope coding sequences 
of SV40 T antigen-transformed antigenic site loss variant cells. 
Variant cells were previously selected by cocultivating SV40- 
transformed C57BL/6 primary kidney cells (K-0) with site- 
specific CTL clones recognizing T antigen epitopes (32, 33). 
Variant cells selected by coculture with CTL clone Y-1 were 
designated K-1. Those selected by coculture with CTL clone 
Y-2 or Y-3 were designated K-2 and K-3, respectively. Cocul- 
ture of K-0 with CTL clone Y-5 selected the variant cell popu- 
lation designated K-5. It was demonstrated that loss of  variant 
cell susceptibility to lysis by T antigen-specific CTL was not 
due to a loss  of T  antigen or MHC class I antigen (32). 
The purpose of this study was to determine the genetic 
basis and molecular mechanism of spontaneous functional loss 
of CTL recognition sites from antigenic site loss variant cells. 
Changes in primary amino acid sequences corresponding to 
the CTL recognition epitopes of SV40 T antigen are shown 
to disrupt the ability of T  antigen to function as a target 
for site-specific CTL clones. 
Materials and Methods 
CTL  Clones.  The generation  and maintenance of SV40 T 
antigen-specific, H-2Db-restricted CTL clones Y-l, Y-2, Y-3, and 
Y-5, and of H-2KLrestricted CTL clone Y-4, have been described 
(28, 30). 
SV40 T Ana'gen Epitope Loss Varianta  and AdditionaI Cel[s.  Anti- 
genic site loss variant cells were derived by coculture of SV40- 
transformed C57BL/6 primary kidney cells (K-0) with SV40 T 
antigen-specific CTL clones (32, 33). For example, K-I ceils were 
selected by coculture with CTL clone Y-l, K-2 cells with CTL 
clone Y-2, and K-1,4,5 cells with Y-l, then Y-4, and then Y-5. Cell 
lines B6/FY derived from a tumor induced by polyoma virus (34), 
and MC57G derived from a tumor induced by methylcholanthrene 
45O 
in a C57BL/6 mouse (35) have been described. All cell lines were 
maintained in DME containing 5 or 10% fetal bovine serum. 
Cytotoxicity  Assays.  Target cell susceptibility to  lysis by T 
antigen-specific  CTL clones  was evaluated  in chromium release  assays 
as described (28, 36). 
Amplificaaon of SV40  DNA  from  Variant Cell Genomes. 
Sequences were amplified  from variant cell genomic DNA (37) ac- 
cording to the specifications  of the GeneAmp DNA Amplification 
Kit (Perkin-Elmer Cetus  Corp.,  Norwalk,  CT).  Supplemental 
MgCI2 was added to 3.5 raM. The thermal cycler program (Step- 
cycle; Perkin-Elmer  Cetus Corp.) used consisted  of  one cycle  denatu- 
ration at 94~  for 2 rain; 29 cycles  of annealing at 51~  for 2 rain, 
extension at 72~  for 3 rain, and denaturation at 94~  for 1 rain; 
and 1 cycle  of annealing at 51~  for 2 rain and extension at 72~ 
for 10 rain. Primary amplification products were isolated by gel 
electrophoresis, band excision, and DNA extraction (GeneClean, 
BIO 101, Inc., La  Jolla, CA). Asymmetric secondary amplification 
(38) was performed  on 100-200 ng of  primary amplification  product, 
with one primer present at 10 nM and the second at 1 #M. Reac- 
tion products were extracted with chloroform, and purified by 
ultrafiltration (Ultrafree MC 30,000 NMW polysulfone,  MiUipore 
Corp., Bedford, MA) in lx  TE. 
PC.R Primers.  Orientations of oligonucleotides used are indi- 
cated by "s" (indicates same sense as T antigen mRNA) or "o" 
(indicates opposite sense). Primers for site I, II, and III primary 
amplifications (spanning SV40 nudeotide (nt) 4760-3233) were 
sS'GGGTTGATTGCTACTGCTTC  ~' and os'TCATGGTGACTA  - 
TTCCA~  3'. For site I, II, and III secondary amplifications 
(spanning nt 4571-3749), primers ss'GC~TTGATTGCTACTGC  - 
TTCWoS'TAGTTAATTGTAGGCTATCAACCCGC  3' were used. 
For some secondary amplifications of sites II and III,  (spanning 
nt 4316-3749), ss'~CTGCTATACAAGAA  3' and oS'TAGTT  - 
AATIGTAGGCTATCAACCCGC  3' were used. For site V primary 
amplifications,  (spanning  nt  4196-3011),  sS'ATTAATAACTA  - 
TGCTCAAGAATTGTGTACCTTTAGC  3' and oS'ATCTCTCTT  - 
TCCACTCCACA  3', or (spanning nt 3850-3011) sS~TGCTGCTA  - 
TATTIGCTGACAGC  3' and oS'ATCTCTCTrTCCACTCCACA  3' 
were used. For  site V  secondary amplifications, (spanning nt 
3850-3137) sS'ATGCTGCTATATrTGCTGACAGC  3' and os'CAC  - 
TGCGTTCCAGGCAATGC  3' were used. 
DNA Sequence Analysis.  Sequendng reactions were carried out 
using Taq DNA polymerase (TaqTrack Sequencing Core System, 
DEAZA; Promega Corp., Madison, WI). Reaction products were 
electrophoresed through 6% acrylamide  gels (SequaGel system;  Na- 
tional Diagnostics, Manville, NJ) in a buffer gradient (39). PCR 
products from separate amplifications were used to sequence the 
complementary strands of variant cell DNA. 
Oligonucleotide-directed ln Vitro Mutagenesis.  Variant  cell-specified 
mutant coding sequences were generated  using the Oligonudeotide- 
directed in vitro Mutagenesis System, version 2 (Amersham Inter- 
national, Amersham, Bucks, UK). Parent phagemids pGC2ESV 
and pGCIESV40pro were constructed by transferring SV40 se- 
quences into the GC-clamp plasmids (40). For plasmid pGC2ESV, 
the SV40 DNA NcoI/BamHI restriction fragment comprising nt 
37-2533, and encompassing the viral origin of replication, early 
region promoter, and complete  T antigen coding region, was ligated 
to the NcoI/BamHI pGC2 vector fragment. Construct pGC2ESV 
was used for mutagenesis, but not for expression of T antigen in 
mammalian cells (due to the lack of SV40 enhancer sequences). 
Mutated sequences were either subcloned from pGC2ESV into 
pGCIESV40pro, or were obtained by direct mutagenesis of  pGC1- 
ESV40pro. The plasmid pGCIESV40pro was generated by con- 
verting the SV40 NaeI site (nt 345) to a SalI site, and inserting 
the SV40 SalI/BamHI fragment into the plasmid pGC1. 
CTL Select for Point-Mutated Cells within Sequences Encoding CTL Epitopes Generation of Cell Lines Expressing Mutant T Antigens.  Mutant 
plasmids were transfected  into adult C57BL/6 mouse primary kidney 
cells (B6/K) as described (41). Transformed colonies were expanded 
for analysis. 
Synthetic Peptides.  Peptides  were synthesized as described pre- 
viously (31). Synthetic peptides used for these studies and corre- 
sponding to wild-type or mutant T antigen CTL recognition sites 
are described in the Results section. Additional peptides used as 
control  peptides  included  the  H-2Db-restricted  influenza  virus 
nudeoprotein CTL recognition epitope NP 365-380 (IASNENM- 
DAMESSTLE) (42) and the T antigen peptide LT 195-209 (LFF- 
LTPHRHRVSAIN). Neither control peptide is recognized by any 
of the SV40 T  antigen-specific CTL clones used in this study. 
Results 
Characterization of Antigenic  Site Loss Variant Cell Lines 
Clonally derived cell lines were generated from the K-l, 
K-2, K-3, and K-5 variant cell populations. The susceptibility 
of each variant cell line to lysis by site-specific  CTL dones 
mirrored  that  of the variant  cell population from which it 
was isolated (32, 33). Data for representative cell lines from 
each variant  group (Table 1) show that  K-1 cdl lines were 
resistant  to lysis by CTL clones Y-l,  Y-2,  and Y-3.  In this 
experiment, lysis of the K-1 cell lines by CTL clone Y-5 was 
depressed relative to Y-5 lysis of K-0. In another experiment, 
CTL clone Y-5 lysed the K-1 cdl lines by CTL done Y-5 
lysis  of K-0.  In another experiment,  CTL done Y-5 lysed 
the K-1 cell lines as well as it did the K-0 cells,  while the 
K-1 cell lines were not lysed by CTL clone Y-1 (data not 
shown). K-2 and K-3 cell lines were resistant to lysis by CTL 
clones Y-2 and Y-3, and K-5 cell lines were resistant to CTL 
done Y-5. Immunoprecipitation  of K-0 and variant cell line 
T antigens using T antigen-specific mAbs PAb 419 (43) and 
PAb 901 (44, 45) indicated that the amino acid and carboxyl 
termini  of the proteins  were intact  (data  not  shown).  As 
demonstrated previously (28, 32, 33), the K-2, K-3, and K-5 
cell lines and the K-0 population expressed apparently full- 
length T  antigen.  A 79-kD T  antigen was immunoprecipi- 
rated from K-1 cell lines  (not  shown). 
Identification of Genetic Lesions Involving CTL  Recognition 
Site  Coding Sequences of Variant Cells 
To determine whether gross deletions or rearrangements 
of SV40 DNA sequences within variant cells could explain 
the loss of CTL recognition  sites,  DNA/DNA  hybridiza- 
tion experiments were performed on variant cell line genomic 
DNA. K-1 cell line DNA cleaved with HindlII was shown 
to carry a deletion within the SV40 HindlII B band specifying 
T antigen amino acids 1-272. This region incorporates CTL 
recognition  sites  I,  II,  and III.  No deletions were detected 
within K-2, K-3, and K-5 cell line T antigen coding sequences. 
Sequence analysis  of viral DNA present within the variant 
cells was conducted. Integrated viral sequences were amplified 
by the PCR, and the amplification reaction products were 
sequenced. 
DNA of the five K-1 cell lines lacked SV40 nt 4421-4030, 
corresponding to the loss of T  antigen amino acid residues 
134-263 (Fig.  1 A). Therefore, loss of CTL recognition sites 
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Table  1.  Lysis of Variant Cells by T Antigen-specific 
CTL Clones 
Percent  specific lysis by CTL clone 
Target cell  Y-1  Y-2  Y-3  Y-4  Y-5 
A. 
B. 
C. 
K-0  99.0  71.5  70.4  90.4  63.3 
K-1 CL3  2.7  0.5  0.3  68.7  34.9 
K-1 CL4  1.3  1.9  1.9  77.0  17.4 
K-1,4,5  1.7  3.7  1.3  3.2  1.0 
K-0  93.0  59.7  69.0  55.9  61.0 
K-2 CL1  79.2  2.4  1.1  19.9  38.7 
K-2 CL4  77.5  0.0  0.0  17.8  33.2 
K-1,4,5  1.0  1.4  0.9  0.7  0.5 
K-0  91.4  20.0  33.0  76.6  25.0 
K-3 CL1  96.5  0.0  0.0  79.1  29.2 
K-3 CL3  86.9  0.0  0.0  59.4  32.6 
K-5 CL2  88.2  74.8  46.4  81.3  0.0 
K-5 CL3  78.9  28.4  33.2  53.5  0.3 
K-1,4,5  3.5  0.0  0.0  1.8  0.0 
Target cells were treated with 3,-IFN before  assay. For these experiments, 
a CTL-to-target cell ratio of 9:1 was used. 
I,  II,  and III from Kol variants was due to the deletion of 
the DNA sequences encoding them. DNA amplifcation and 
sequencing also were performed for the population K-1,4,5. 
K-1,4,5 had been selected by sequential coculture of K-1 with 
Y-4 and then Y-5 (33), and was resistant  to lysis by CTL dones 
Y-l, Y-2, Y-3, Y-4, and Y-5. The deletion present within the 
I(-1 cell lines was also present in cells of the K-1,4,5 popula- 
tion. The basis for CTL recognition site loss was determined 
for an independently sdected CTL Y-l-resistant variant cell 
population. K-3,1 cells had been selected by coculture of CTL 
clone Y-3 sdected cells (1(-3) with Y-1 (32), and lacked CTL 
recognition sites I, II, and III. The K-3,1 T  antigen was of 
apparent  size 81 kD (32),  suggesting that the genetic basis 
for antigenic site loss in K-3,1 differed from that of the K-1 
cells.  Amplified I(-3,1 DNA was sequenced. A  ddetion of 
SV40 nt 4348-4114, with a C-to-A transversion at nt 4113, 
was detected (Fig.  1 A).  The K-3,1 T  antigen lacks amino 
acids 157-234, with the substitution of aspartic acid for ala- 
nine at position 235. Coding sequences for CTL recognition 
sites  I,  II,  and III are absent. 
Sequences for the five K-2 cdl lines showed a single point 
mutation at SV40 nt 4134 (Fig.  1 B). The G-to-T transver- 
sion substitutes asparagine for lysine as T antigen amino acid 
228.  The sequence from each K-3 cell line DNA indicated 
an A-to-T transversion  at SV40 nt 4129 (Fig. 1 B), substituting 
phenylalanine for tyrosine as T antigen amino acid 230. Both 
the K-2 and K-3-substituted amino acids lie within the defined 
minimal  site II/III  CTL recognition  epitope. 4205  nt  4175 
WT  GTG  TCT  GCT  ATI" AAT  AAC  TAT  GCT  CAA  AAA  qTG 
K-1  .........  (A4421-4030) 
..........  (A4348-4I 14) 
K-3,1  ~,~f~/.///f/~//~  sitel  ~/'~/'~/'~/q 
WT  val  ser  ala  ile  ash  asn  tyr  ala  gin  lys  leu 
K-I  ......  (A134-263) 
K-3,1  ......  (A157-234) 
205  amino  acid  215 
4151  nt  4119 
WT  TGT  AAA  GGG  GTF  AAT  AAG  GAA  TAT  "I-FG  ATG  TAT 
K-2  *  *  *  *  *  AAT  *  *  *  * 
K-3  *  *  *  *  *  *  *  TIT  *  *  * 
WT  cys  lys  gly  val  ash  lys  glu  lyr  leu  met  tyr 
K-2  *  "  *  *  *  asn  *  "  *  *  " 
K-3  *  "  "  *  "  *  "  phe  * 
223  amino  acid  23I 
3353  nt  3309 
WT  CAGGGA  ATTAATAACCTGGAC  AAT  TTA  AGG  GATTATTTG  GATGGC 
K-5  *  *  *  *  *  *  *  ATT  *  *  *  *  *  *  * 
K-1,4,5  *  *  "ITI"  *  *  *  *  *  *  *  *  *  *  *  * 
WT  gin  gly  ile  asn  ash  leu  asp  ash  leu  arg  asp  tyr  leu  asp  gly 
K-5  *  *  *  *  *  *  *  lie  *  *  *  *  *  *  * 
K-I,4,5  *  *  phe  *  *  *  *  *  *  *  *  *  *  *  * 
489  amino  acid  503 
Figure 1.  Mutations  identified  within T antigen CTL recognition  site 
coding sequences  of variant calls. The "WT" SV40 nndeotide  and amino 
acid numbers  indicate  K-0 sequences  encoding  or comprising, respectively, 
minimal or functional  CTL recognition  sites (32, 33). (*) Variant cell se- 
quences identical to those of the K-0 population. (-) Sequences deleted 
from variant cells, but present in K-0 cells. Amino acid substitutions or 
deletions (A) specified  by variant  cell  DNA mutations are shown  beneath 
the WT amino acid sequence. Deletions  within K-1 cell line and K-3,1 
population DNA (A) extend  beyond  the minimal site I sequences.  Muta- 
tions present within variant cells lacking site 1I/III (B) or site V (C) are 
shown. Minimal site V sequences,  as defined  by synthetic  peptide studies 
(32), comprise  T antigen amino acids 489-497. These residues are indi- 
cated in italics within the WT site V amino acid sequence  489-503 used 
for these experiments. 
K-5 cell line DNA  sequences showed a point mutation 
within the coding sequences for CTL recognition site V. An 
A-to-T transversion at SV40 nt 3331  specifies the substitu- 
tion of isoleucine for asparagine as T antigen amino acid 496 
(Fig.  1 C). Sequence data for the site V coding region from 
K-1,4,5 amplifications indicated a point mutation at SV40 
nt 3347 (A-to-T), specifying the substitution of phenylala- 
nine for isoleucine as T  antigen amino acid 491 (Fig. 1 C). 
Amino acids 496 and 491 both lie within the mapped recog- 
nition site for CTL clone Y-5. 
Effects of  Mutations Identified b  7 PCR Amplification and Sequence 
Analysis  on CTL Recognition 
Generation of Cell Lines Expressing T Antigens Carrying the 
1(-2,1(-3,1(-5, or 1(-1,4,5 Mutations and Effect of these Mutations 
on CTL Recognition.  To confirm that each substitution was 
sufficient to disrupt CTL recognition sites II and III or V, 
the point mutations identified by PCP, amplification and se- 
quence analysis were introduced individually into an expres- 
sion construct carrying the coding sequences  for wild-type 
T  antigen. Mutant constructs were used for transfection of 
primary C57BL/6 kidney cells.  Foci of immortalized cells 
were expanded and screened for the presence of the appro- 
priate  wild-type  or  substituted  nucleotides  by  DNA  se- 
quencing of PCR amplified products.  In all cases, the sequences 
corresponded to those of the transfected construct (data not 
shown). Cells were then screened for expression ofT antigen 
by immunofluorescence  and immunoprecipitation. Each trans- 
formant produced a nuclear T antigen of '~94 kD (data not 
shown). Cell lines expressing wild-type or mutant T antigen 
were designated B6/SV-T wt, B6/SV-T228(lys--~asn), B6/SV- 
T230(tyr--~phe),  B6/SV-T496(asn-*ile),  or  B6/SV-T491- 
(ile~phe) (Table 2). 
The cell lines were assayed for their susceptibility to CTL 
clones Y-l, Y-2, Y-3, and/or Y-5. As shown in Fig. 2 A, B6/SV- 
T228(lys---~asn) cells were not lysed by either CTL clone Y-2 
Table 2.  Mutant DNA  Constructs Carrying Variant-specified  Substitutions and Synthetic Peptides 
Mutation identified within  Corresponding  CTL 
Cell  CTL recognition  site  Cell line reconstructing  recognition  site 
population/line  coding  sequences  the identified mutation  synthetic peptide 
Synthetic peptide 
amino acid sequence 
K-0  none  B6/SV-T wt  LT 205-215 
K-0  none  B6/SV-T wt  LT 207-215 
K-0  none  B6/SV-T wt  LT 223-231 
K-2  G-*T substitution,  nt 4134  B6/SV-T228(lys-*asn)  LT 223-231 
K-3  A--*T substitution,  nt 4129  B6/SV-T230(tyr--*phe)  LT 223-231 
K-0  none  B6/SV-T wt  LT 489-503 
K-1,4,5  A--~T substitution,  nt 3347  B6/SV-T491  (ile-*phe)  LT 489-503 
K-5  A--*T substitution,  nt 3331  B6/SV-T496  (asn--*ile)  LT 489-503 
(228 lys-*asn) 
(230 tyr~phe) 
(491 ile--~phe) 
(496 asn-*ile) 
VSAINNYAQKL 
AINNYAQKL 
CKGVNKEYL 
CKGVNNEYL 
CKGVNKEFL 
QGINNLDNLRDYDG 
QGFNNLDNLRDYDG 
QGINNLDILRDYDG 
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Figure 2.  CTL recognition site losses  caused  by introduction of variant 
cell T antigen mutations into wild-type T antigen. Cell lines carrying 
individual K-2 or K-3 cell  line mutations (,4) or K-5 cell  line or K-1,4,5 popu- 
lation mutations (B) in a wild-type T antigen background were tested 
for susceptibility to lysis by T antigen-specific CTL clones. A standard 
cytotoxidty assay was used, with a CTL-to-target ceil ratio of 9:1. 
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Figure 3.  W/ld-type  and substituted synthetic peptides as targets for 
CTL recognition. MC57G ceils pulsed with site lI/IIl wild-type or sub- 
stituted peptides were used as target cells for CTL clones Y-l, Y-2, and 
Y-3 (A). Recognition of site V wild=type  and mutant peptides by CTL 
clones Y-1 and Y=5 (B) was also evaluated. For peptide pulsing, tOO ~M 
peptide solutions were used. The CTL-to-target cell ratio was 5:1. 
or Y-3.  B6/SV-T230(tyrophe)  cells also were not lysed by 
either Y-2 or Y-3. However, both cell lines were lysed by CTL 
clone Y-l, indicating that H-2D  b class I antigen in these cell 
lines was functional.  Thus,  either  of the point  mutations 
identified within K-2 or K-3 cell lines was sufficient to cause 
loss of recognition by both CTL Y-2 and Y-3. 
The results for the B6/SV:F496(asn-)ile) cell line, carrying 
a mutation in the coding region for CTL recognition  site 
V,  are shown in Fig. 2 B. B6/SV-T496(asn-~ile)  cells were 
not lysed by CTL clone Y-5, however, they were lysed by 
CTL clone Y-1. Therefore, resistance to Y-5 could be attrib- 
uted directly to the substitution at T antigen amino acid 496. 
B6/SV-T491(ile-*phe) cell line, which contains the muta- 
tion  identified  in  the  independently  derived  CTL  clone 
Y-5-resistant population K-1,4,5, was resistant to lysis by CTL 
clone Y-5, yet maintained susceptibility to lysis by CTL clone 
Y-1 (Fig. 2 B). These results indicate that amino acid substi- 
tution at position 491 also leads to loss of site V recognition. 
Loss of CTL Recognition Site Function by Synthetic Peptides 
Representing Mutant CTL Recognition Sites.  To determine 
whether synthetic peptide reconstruction  of CTL recogni- 
tion sites (42) could be used to define mechanisms of variant 
cell CTL recognition site loss, cytotoxicity assays were car- 
ried out on peptide-pulsed H-2  b target cells (MC57G) that 
did not express endogenous T antigen. The mutant peptides 
(Table 2) used for analysis of K-2 and K-3 T antigen substitu- 
tions  (LT  223-231  [228  lys~asn]  and  LT  223-231  [230 
tyr-~phe])  were not recognized by either CTL clones Y-2 
or Y-3 (Fig.  3 A). 
Peptides corresponding to T antigen amino acids 489-503 
were used for analysis of site V substitutions, as minimal site 
V had not been delimited within amino acids 489-497 (31) 
when these experiments were initiated. CTL clone Y-5-medi- 
ated lysis of MC57G  cells pulsed with  LT 489-503  (496 
asn~ile) was suppressed relative to lysis of cells pulsed with 
the wild-type (LT 489-503) peptide (Fig. 3 B). Mutant pep- 
tide LT 489-503 (491 ile~phe) failed to provide a target for 
CTL done Y-5. 
Presentation of Mutant Peptides by H-2D  b Class l Antigens. 
To determine whether the mutant peptides can be presented 
by the  H-2D  b class  I  antigen,  peptide  competition  assays 
(46, 47) were undertaken.  StCr-labeled target cells were in- 
cubated with a constant amount of wild-type peptide mixed 
with increasing amounts of mutant peptide before exposure 
to CTL clones. Increasing concentrations of site II/III mu- 
tant peptides (LT 223-231  [228 lys~asn]  and LT 223-231 
[230 tyr~phe]) progressively decreased the ability of the wild- 
type peptide LT 223-231 to provide a target for CTL done 
Y-2 (Fig. 4 A) and CTL done Y-3 (Fig. 4/3). This indicated 
that the mutant peptides were able to bind to class I MHC 
H-2D  b. As shown in Fig. 4 A, the influenza virus NP pep- 
tide failed to compete ef~ciently against the site II/III wild- 
type peptide in this experiment at the concentrations indicated. 
The ability of the mutant site V peptides to associate with 
the class I H-2D  b molecule also was assessed through a stan- 
dard competition assay. Peptide LT 489-503 (491 ile-~phe) 
was able to bind to class  I H-2D  b antigen,  as reflected by 
the reduction in target cell lysis by CTL clone Y-5 at increasing 
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Figure 4.  Binding  to MHC class I H-2D  b antigen of substituted syn- 
thetic peptides corresponding  to variant cell mutant T antigen CTL rec- 
ognition sites. Binding  of  amino acid-substituted  peptides  to class I MHC 
H-2D  b antigen was evaluated  in a peptide competition  assay. Target  cells 
were pulsed simultaneously  with wild-type  peptides at constant concen- 
tration and substituted  peptides  at variable  concentrations  (see  figure  axes). 
Target cells and wild-type  peptide concentrations  used were (A) K-1,4,5 
calls with 1 #M LT 223-231, and (B) MC57G cells with 1.57 #M LT 
489-503. Additional  peptides included  NP 365-380, LT 195-209, and LT 
205-215 (site I peptide). The CTL-to-target cell ratio was 5:1. 
concentrations of mutant competitor peptide (Fig. 4 CO. The 
ability of LT 489-503 (496 asn~ile) to compete with wild- 
type peptide could not be addressed. As shown in Fig. 3 B, 
this peptide is recognized by CTL done Y-5, albeit with a 
much lower efficiency than the wild-type peptide. 
These studies show that the mutant peptides bind to class 
I H-2D  b molecules. It seems likely, therefore, that CTL rec- 
ognition site loss in the variant cells is effected at the level 
of epitope interaction with the TCR. 
Discussion 
The SV40 transforming protein, T antigen, is a multifunc- 
tional gene product possessing an array of biochemical ac- 
tivities that map to discrete structural domains of the pro- 
tein (27). Domains involved in the transformation of primary 
mouse embryo fibroblasts (B6/MEF) in culture and in con- 
ferral of tumorigenicity in vivo have been defined (44, and 
references therein). Cells transformed in vitro by T  antigen 
acquire the phenotype of tumor cells, and are transplantable 
in athymic nude mice (44). The T antigen is novel as a trans- 
forming gene product in that it has been shown to provide 
a target for host immune rejection of the transformed cell. 
The protein is processed intracdlularly into CTL recogni- 
tion elements, which are presented at the cell surface in the 
context of class I MHC antigens and induce class I-restricted 
CTL responses in responder hosts. Since T antigen is required 
for maintenance as well as for initiation of the transformed 
phenotype, and as its tumorigenic function is modulated by 
the cellular immune response, it is an ideal experimental on- 
cogene product for evaluating how mutations within trans- 
forming protein CTL epitopes enhance or disrupt antitumor 
immunity. The T antigen domains constituting CTL recog- 
nition epitopes are defined, the regions required for transfor- 
mation are broadly mapped, and T antigen-transformed cells 
carrying point mutations disrupting CTL recognition sites 
have been characterized in this study. Therefore, the genetic 
information and biological reagents for dissecting the con- 
tribution of individual CTL recognition sites to host rejec- 
tion of transformed cells, and for analysis of differential host 
ability to respond to mutant transforming proteins, are readily 
available in this system. 
The results reported here demonstrate that CTL specific 
for a transforming protein select for survival of transformed 
cells bearing disrupted CTL epitopes. Deletions have been 
shown to inactivate a subset of CTL recognition sites. How- 
ever, single point mutations inducing amino acid substitu- 
tions within recognition epitopes are sufficient for the elimi- 
nation of most sites. Each of the mutant CTL recognition 
epitopes identified within the T antigen epitope loss variant 
cells retains the ability to associate with MHC class I H-2D  b 
antigen. Preliminary experiments designed to compare the 
H-2Db-binding efficiencies of substituted CTL recognition 
sites with those of the wild-type sites (48) indicate that the 
substituted synthetic peptides used in this study bind to MHC 
class I H-2D  b as efficiently as, or better than, their wild-type 
counterparts (N. Lill and S. Tevethia, unpublished data). This 
suggests that the variant-specified amino acid substitutions 
disrupt target cell recognition at the level of epitope interac- 
tion with the TCR. 
CTL recognition of tumor antigens has been shown to 
inhibit tumor development and progression (1, 29, 49, 50). 
Loss of tumor cell susceptibility to CTL may contribute to 
the progressive growth of tumor cells. Five immunologically 
distinct H-2b-restricted CTL recognition sites within T an- 
tigen have been mapped (28, 30,  31).  This multiplicity of 
CTL recognition sites provides a backup to guard against 
the complete loss of transformed cell susceptibility to CTL. 
454  CTL Select for Point-Mutated Cells within Sequences Encoding CTL Epitopes It is unlikely that, under active immune surveillance in vivo, 
transformed cells lacking multiple sites will accumulate be- 
fore they can be eliminated by CTL reactive against at least 
one of the recognition sites. However, it must be empha- 
sized that a transformed cell population (K-1,4,5) expressing 
T  antigen and resistant to CTL clones spedfic for each of 
the five mapped epitopes, has been selected (33). Even if such 
cells arise with low frequency, their appearance would have 
significant implications for tumor progression. 
The present study has dealt with variants selected from 
a population of cells transformed by wild-type SV40. Based 
on our results, we hypothesize that point mutations within 
CTL epitope coding sequences of transforming proteins may 
allow escape of tumor cells from active immunosurveillance 
in vivo. SV40 T  antigen contains domains required for im- 
mortalization of primary cells and for conferral of other aspects 
of the transformed phenotype, including loss of contact in- 
hibition, decreased  growth factor dependence, anchorage- 
independent growth, and conferral of cellular tumorigenic 
potential (44). The presence of T  antigen containing these 
domains is required continuously for maintenance of the fully 
transformed phenotype (27, 44). The antigenic site loss variant 
cells analyzed in this study, and the corresponding "recon- 
struction" cell lines generated by transfection of murine pri- 
mary cell cultures with appropriate mutant coding sequences, 
respectively maintained and acquired the immortalized pheno- 
type characteristic  of SV40-transformed cells. Although the 
tumorigenicity of the variant cells used in this study has not 
been tested, the functions of T antigen that are sufficient to 
immortalize B6/MEF and those that are involved in confer- 
ring tumorigenicity colocalized  to T  antigen amino acids 
250-625 (44). Three of the four H-2Db-restricted CTL epi- 
topes are located outside of the immortalization-tumorige- 
nicity domain. It is anticipated, therefore, that the variants 
and reconstruction cell lines will form tumors efficiently in 
nude mice. The T  antigen residues altered by point muta- 
tions in variant CTL recognition epitope V lie within the 
immortalization-tumorigenicity domain. The site V recon- 
struction plasmids immortalize B6/MEF as efficiently as wild- 
type, and the resulting cell lines appear fully transformed in 
cell cultur~ We infer, therefore, that they also will form tumors 
in nude mice. 
Targeted immune therapeutic approaches against tumor cells 
would ideally be directed against antigens that must be ex- 
pressed by all of the tumor cells. Transforming proteins re- 
quired for maintenance of the transformed phenotype and 
containing CTL  epitopes represent ideal  targets for such 
therapy.  In the SV40 variant cell model system, T  antigen 
provides the target for CTL, but also confers a selective cel- 
lular  survival  advantage (cellular  immortalization). SV40- 
transformed cells acquiring spontaneous mutations that com- 
promise cellular transformation would not survive during the 
CTL selection period because of loss of immortalization. In 
this sense, the T  antigen model system differs from other 
model systems in which the CTL target antigens are prob- 
ably not required for maintenance of cellular transformation 
(26). Immune responses targeted against nontransforming an- 
tigens would be ineffective in preventing malignant growth 
of transformed cells that had lost expression of those antigens. 
In the case of transforming proteins such as T antigen, loss 
of entire protein expression would render the cell nonsus- 
ceptible to antigen-specific  immune responses, but that cell 
would concurrently lose potential for tumorigenicity, as the 
domains ofT antigen are continuously required for the main- 
tenance of transformed state. For this reason, T antigen and 
other CTL epitope-bearing transforming proteins such as the 
activated ms oncogene (51, 52) may represent the preferred 
targets for immune therapy. CTL epitope loss from these pro- 
teins may have a significant impact on transformed cell sur- 
vival and tumor progression in vivo. 
Spontaneous mutations resulting in the loss of CTL rec- 
ognition sites from antigens have significant implications for 
the development and persistence of diseases states. CTL rec- 
ognition site loss variants have been demonstrated in the lym- 
phocytic choriomeningitis (LCMV) model system in vivo (53) 
and in vitro (54). In these cases, epitope loss was caused by 
point mutations within antigen-coding sequences, and led 
to virus persistence in vivo (53). It has also been shown that 
T cell-resistant variants of the HIV arise in vivo during the 
course of infection (55). The accumulation of escape variants 
may, in this case, contribute to HIV escape from immunosur- 
veillance. We have determined through the analysis of SV40- 
transformed antigen loss variant cells that single amino acid 
substitutions within CTL recognition sites are sufficient to 
abrogate transformed cell lysis by site-specific CTL clones. 
Our results suggest that, in principle, cumulative minimal 
genetic mutations may result in sequential CTL recognition 
epitope loss with concomitant escape of the transformed cell 
from immune surveillance. This study extends the number 
of potential mechanisms whereby SV40-transformed cells can 
escape lysis by CTL, and provides information required for 
further dissection of the relative contribution that individual 
CTL recognition sites make toward the host defense against 
tumor cells. 
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